Biocon announced the launch of its GLP-1 peptide, Liraglutide, for diabetes and obesity, in the United Kingdom (U.K.). The drug-device combination will be marketed in the U.K. under the brand names Liraglutide Biocon for diabetes (gVictoza�) and Biolide for chronic weight management (gSaxenda�). The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K., earlier this year, making Biocon the first generics company to obtain approval for gLiraglutide in a major regulated market. Powered by Capital Market - Live News

Net profit of Biocon declined 96.20% to Rs 25.10 crore in the quarter ended December 2024 as against Rs 660.00 crore during the previous quarter ended December 2023. Sales rose 6.32% to Rs 3773.00 crore in the quarter ended December 2024 as against Rs 3548.70 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales3773.003548.70 6 OPM %19.9325.44 - PBDT563.201201.50 -53 PBT137.80787.00 -82 NP25.10660.00 -96 Powered by Capital Market - Live News

The Board of Biocon at its meeting held on 27 January 2025 has approved the issuance of commercial paper of Rs 570 crore on private placement basis. Powered by Capital Market - Live News

Biocon announced its Environmental, Social and Governance (ESG) scores as assessed by S&P Global`s Corporate Sustainability Assessment (CSA) for 2024. Biocon achieved a notable improvement with an S&P Global ESG Score of 69 in 2024, up 6 points from 63 in 2023. This places the Company in the 98th percentile among its global biotechnology industry peers. Biocon achieved an ESG Score of 76 in the Environmental Dimension, 74 in the Social Dimension, and 62 in the Governance & Economic Dimension. Biocon`s subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score core of 53Powered by Capital Market - Live News

Biocon will hold a meeting of the Board of Directors of the Company on 27 January 2025.Powered by Capital Market - Live News